A Multicenter, Open-Label Phase I/II Trial of the Safety and Efficacy of the dHER2 Recombinant Protein Combined With Immunological Adjuvant AS15 in Patients With Metastatic Breast Cancer Overexpressing HER2/Neu.
Phase of Trial: Phase I/II
Latest Information Update: 18 May 2017
At a glance
- Drugs Cancer vaccine HER-2 neu (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 13 Oct 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
- 13 Oct 2009 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.